AR122180A1 - Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl - Google Patents

Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl

Info

Publication number
AR122180A1
AR122180A1 ARP210101427A ARP210101427A AR122180A1 AR 122180 A1 AR122180 A1 AR 122180A1 AR P210101427 A ARP210101427 A AR P210101427A AR P210101427 A ARP210101427 A AR P210101427A AR 122180 A1 AR122180 A1 AR 122180A1
Authority
AR
Argentina
Prior art keywords
methods
ldl cholesterol
related disorders
pcsk9 inhibitors
treat
Prior art date
Application number
ARP210101427A
Other languages
English (en)
Spanish (es)
Inventor
Andrew W Hamer
Ian Matthew Bridges
Huei Wang
Andrea Ruzza
Christopher Kurtz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR122180A1 publication Critical patent/AR122180A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ARP210101427A 2020-05-29 2021-05-27 Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl AR122180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29

Publications (1)

Publication Number Publication Date
AR122180A1 true AR122180A1 (es) 2022-08-24

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101427A AR122180A1 (es) 2020-05-29 2021-05-27 Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl

Country Status (11)

Country Link
US (1) US20230235085A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157887A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023527542A (cg-RX-API-DMAC7.html)
CN (1) CN115916838A (cg-RX-API-DMAC7.html)
AR (1) AR122180A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021281256A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179316A1 (cg-RX-API-DMAC7.html)
IL (1) IL298375A (cg-RX-API-DMAC7.html)
JO (1) JOP20220322A1 (cg-RX-API-DMAC7.html)
TW (1) TW202210524A (cg-RX-API-DMAC7.html)
WO (1) WO2021243002A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
WO2025036347A1 (zh) 2023-08-14 2025-02-20 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
KR20230074283A (ko) * 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법

Also Published As

Publication number Publication date
JP2023527542A (ja) 2023-06-29
US20230235085A1 (en) 2023-07-27
CN115916838A (zh) 2023-04-04
EP4157887A4 (en) 2024-07-03
JOP20220322A1 (ar) 2022-11-27
TW202210524A (zh) 2022-03-16
CA3179316A1 (en) 2021-12-02
EP4157887A1 (en) 2023-04-05
AU2021281256A1 (en) 2022-12-22
IL298375A (en) 2023-01-01
WO2021243002A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JOP20220322A1 (ar) مثبطات pcsk9 وطرق استخدامها لعلاج الاضطرابات المرتبطة بالكوليسترول
CO2026004964A2 (es) Moduladores de kras
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
EP4403213A3 (en) Methods for reducing cardiovascular risk
BR112018076242A2 (pt) inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1
NO20082907L (no) Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer
CY1121379T1 (el) Πολυθεραπεια για την ισχαιμια
CR20130640A (es) Métodos para tratar o prevenir trastornos relacionados con el colesterol
MX2019013634A (es) Composiciones y metodos para tratar cancer con mutaciones de braf atipicas.
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
MX2015005536A (es) Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
BR112022023048A2 (pt) Tratamento de combinação de distúrbios hepáticos
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CU24110B1 (es) Compuestos y composiciones como inhibidores de cinasa de proteína
ECSP034478A (es) Combinacion terapeutica
ECSP10010289A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada
MX388694B (es) Compuestos neuroactivos y metodos de uso de los mismos.
BR112013002541A2 (pt) uso de ligante sigma, combinação de pelo menos um ligante sigma e de pelo menos um composto opióide ou opiato para administração simultânea, separada ou sequencial e método de tratamento de um paciente que sofre de oih associada à terapia opióide
ES2689971T3 (es) Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2022013081A (es) Compuestos para el tratamiento de sars.
PE20211065A1 (es) Metodo para tratar la epilepsia
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
CL2007002381A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis